Market Closed -
Nasdaq
04:30:01 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
19.74
USD
|
-1.00%
|
|
+17.85%
|
-14.58%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
167.6
|
99.56
|
414.9
|
119.3
|
1,088
|
1,028
|
-
|
-
|
Enterprise Value (EV)
1 |
167.6
|
99.56
|
414.9
|
119.3
|
806.6
|
813.4
|
679.9
|
536.9
|
P/E ratio
|
-2.87
x
|
-1.86
x
|
-6.03
x
|
-1.28
x
|
-12.7
x
|
-10.4
x
|
-6.57
x
|
-6.01
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
8.23
x
|
2.89
x
|
11.2
x
|
2.88
x
|
23.6
x
|
26.7
x
|
87.9
x
|
116
x
|
EV / Revenue
|
8.23
x
|
2.89
x
|
11.2
x
|
2.88
x
|
17.5
x
|
21.1
x
|
58.1
x
|
60.4
x
|
EV / EBITDA
|
-4.12
x
|
-2.87
x
|
-
|
-
|
-
|
5.09
x
|
3.64
x
|
2.28
x
|
EV / FCF
|
-2.94
x
|
-6.73
x
|
-8.26
x
|
-1.78
x
|
-502
x
|
-8.28
x
|
-5.27
x
|
-4.5
x
|
FCF Yield
|
-34%
|
-14.9%
|
-12.1%
|
-56.3%
|
-0.2%
|
-12.1%
|
-19%
|
-22.2%
|
Price to Book
|
-
|
-
|
-
|
-
|
4.26
x
|
5.62
x
|
3.61
x
|
2.96
x
|
Nbr of stocks (in thousands)
|
10,812
|
15,130
|
33,894
|
34,083
|
47,074
|
52,084
|
-
|
-
|
Reference price
2 |
15.50
|
6.580
|
12.24
|
3.500
|
23.11
|
19.74
|
19.74
|
19.74
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
20.36
|
34.44
|
36.94
|
41.4
|
46.02
|
38.54
|
11.7
|
8.893
|
EBITDA
1 |
-40.69
|
-34.64
|
-
|
-
|
-
|
159.9
|
186.9
|
235.3
|
EBIT
1 |
-47.86
|
-37.29
|
-55.28
|
-78.94
|
-75.07
|
-103.4
|
-159.3
|
-183.6
|
Operating Margin
|
-235.02%
|
-108.28%
|
-149.64%
|
-190.65%
|
-163.13%
|
-268.35%
|
-1,361.96%
|
-2,064.93%
|
Earnings before Tax (EBT)
1 |
-56.79
|
-45.39
|
-58.42
|
-102.3
|
-70.71
|
-92.39
|
-152.6
|
-184.7
|
Net income
1 |
-56.79
|
-45.39
|
-58.42
|
-102.3
|
-70.8
|
-93.34
|
-156.4
|
-184.8
|
Net margin
|
-278.88%
|
-131.82%
|
-158.14%
|
-246.97%
|
-153.84%
|
-242.18%
|
-1,336.8%
|
-2,078.03%
|
EPS
2 |
-5.400
|
-3.540
|
-2.030
|
-2.740
|
-1.820
|
-1.903
|
-3.003
|
-3.286
|
Free Cash Flow
1 |
-56.91
|
-14.8
|
-50.25
|
-67.16
|
-1.608
|
-98.27
|
-129
|
-119.4
|
FCF margin
|
-279.46%
|
-42.97%
|
-136.04%
|
-162.19%
|
-3.49%
|
-254.95%
|
-1,102.6%
|
-1,342.05%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
9.059
|
11.54
|
9.294
|
11.56
|
10.01
|
10.53
|
7.683
|
9.105
|
15.2
|
14.03
|
9.135
|
9.017
|
9.457
|
8.525
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
42
|
-
|
EBIT
1 |
-15.31
|
-18.05
|
-18.28
|
-19.22
|
-18.4
|
-23.04
|
-21.55
|
-22.76
|
-14.4
|
-16.35
|
-21.94
|
-23.77
|
-27.17
|
-30.55
|
Operating Margin
|
-169.04%
|
-156.36%
|
-196.73%
|
-166.16%
|
-183.76%
|
-218.7%
|
-280.54%
|
-249.98%
|
-94.71%
|
-116.58%
|
-240.16%
|
-263.6%
|
-287.24%
|
-358.32%
|
Earnings before Tax (EBT)
1 |
-16.7
|
-19.43
|
-20.98
|
-19.41
|
-18.42
|
-43.45
|
-21.16
|
-22.92
|
-12.61
|
-14.02
|
-19.2
|
-21.04
|
-24.43
|
-27.77
|
Net income
1 |
-16.7
|
-19.43
|
-20.98
|
-19.41
|
-18.42
|
-43.45
|
-21.16
|
-22.92
|
-12.61
|
-14.1
|
-19.2
|
-21.04
|
-24.43
|
-27.77
|
Net margin
|
-184.29%
|
-168.33%
|
-225.69%
|
-167.8%
|
-183.98%
|
-412.53%
|
-275.47%
|
-251.73%
|
-82.96%
|
-100.51%
|
-210.15%
|
-233.37%
|
-258.29%
|
-325.77%
|
EPS
2 |
-0.5800
|
-0.5900
|
-0.5600
|
-0.5200
|
-0.4900
|
-1.160
|
-0.5600
|
-0.6100
|
-0.3300
|
-0.3300
|
-0.3852
|
-0.4300
|
-0.4958
|
-0.5892
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/3/21
|
3/3/22
|
5/4/22
|
8/3/22
|
11/2/22
|
3/2/23
|
5/3/23
|
8/2/23
|
11/1/23
|
3/7/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
281
|
215
|
348
|
491
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-56.9
|
-14.8
|
-50.3
|
-67.2
|
-1.61
|
-98.3
|
-129
|
-119
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-39%
|
-44.4%
|
-71.9%
|
-59.7%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-26.4%
|
-33.9%
|
-59.4%
|
-51.7%
|
Assets
1 |
-
|
-
|
-
|
-
|
267.8
|
275.1
|
263.3
|
357.4
|
Book Value Per Share
2 |
-
|
-
|
-
|
-
|
5.430
|
3.510
|
5.470
|
6.670
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.21
|
0.36
|
0.16
|
2.15
|
3.48
|
2.73
|
2.43
|
3.4
|
Capex / Sales
|
1.05%
|
1.05%
|
0.42%
|
5.19%
|
7.57%
|
7.09%
|
20.8%
|
38.23%
|
Announcement Date
|
3/5/20
|
3/4/21
|
3/3/22
|
3/2/23
|
3/7/24
|
-
|
-
|
-
|
Last Close Price
19.74
USD Average target price
43.89
USD Spread / Average Target +122.33% Consensus |
1st Jan change
|
Capi.
|
---|
| -14.58% | 1.03B | | +21.85% | 546B | | -4.77% | 359B | | +16.97% | 323B | | +5.69% | 290B | | +13.68% | 234B | | +3.65% | 198B | | -11.12% | 194B | | +8.08% | 167B | | -3.40% | 157B |
Other Pharmaceuticals
|